Share on LinkedInShare on LinkedIn

ARTICLE · 03 OCTOBER 2014

CETA Text Released: Patent Term Restoration For Pharmaceutical/Biologic Patents Coming To Canada

As reported in the IP Update, Text of CETA released the text of CETA was released on September 26, 2014.

CanadaIntellectual Property

As reported in the IP Update, Text of CETA released the text of CETA was released on September 26, 2014. As reported in that article, CETA, Chapter 22 in particular, includes provisions specifically impacting pharmaceuticals/biologics in three areas: (i) patent term restoration (PTR); (ii) innovator right of appeal under the Patented Medicines (Notice of Compliance) Regulations; and (iii) data protection. See also our November 14, 2013 article: Comprehensive Economic and Trade Agreement between Canada and Europe to result in greater protection for pharmaceutical patentees.

This article provides more details regarding the patent term restoration provision, Article 9.2, entitled Sui Generis [Latin for "unique"] protection for Pharmaceuticals. Broadly, this form of protection effectively extends patent term to account for marketing delays resulting from the time required to obtain regulatory approval. While the EU has had patent term restoration - granted by way of sup

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from